Press Releases

Grünenthal (the “Company”) today announced the pricing of €850 million senior secured notes due 2032 (the “Notes”), comprising €400 million aggregate principal amount of 5.375% senior secured fixed rate notes and €450 million aggregate principal amount of senior secured floating rate notes at Euribor + 275 basis points, both due 2032.

Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients.

By organising its own staging of the 2026 Kinder-Lebens-Lauf, Grünenthal has today sent a clear signal of its support for critically ill children and their families.

Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).

Grünenthal certified as family-Grünenthal has once again been recognised for its commitment to improving the work-life balance of its employees. As part of the ‘berufundfamilie’ audit, the Aachen-based pharmaceutical company’s certificate has been extended for a further three years with a distinction.

Grünenthal announced today that the company successfully concluded a Phase I trial evaluating the safety and tolerability of its proprietary NOP agonist.

Grünenthal, a global leader in pain management and research, has published exceptional 2025 financial results, marking a year of record-high profitability and operational excellence.